Recombinant Human G-CSF/CSF3 Protein (Fc Tag)(Active)
SKU: PKSH031938-100
Recombinant Human G-CSF/CSF3 Protein (Fc Tag)(Active)
SKU # | PKSH031938 |
Expression Host | HEK293 Cells |
Description
Synonyms | C17orf33, CSF3, Filgrastim, G-CSF, GCSF, Granulocyte Colony-Stimulating Factor, Lenograstim, Pluripoietin |
Species | Human |
Expression Host | HEK293 Cells |
Sequence | Ala 30-Pro 204 |
Accession | NP_757373.1 |
Calculated Molecular Weight | 45.4 kDa |
Observed Molecular Weight | 48 kDa |
Tag | N-hFc |
Bio-activity | Measured in a cell proliferation assay using a murine myeloblastic cell line, NFS-60.The ED50 for this effect is typically 0.2-0.8 ng/ml. |
Properties
Purity | > 97 % as determined by reducing SDS-PAGE. |
Endotoxin | < 1.0 EU per μg of the protein as determined by the LAL method. |
Storage | Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months. |
Shipping | This product is provided as lyophilized powder which is shipped with ice packs. |
Formulation | Lyophilized from sterile 100mM Glycine, 10mM NaCl, 50mM Tris, pH 7.5 Normally 5% - 8% trehalose, mannitol and 0.01% Tween 80 are added as protectants before lyophilization. Please refer to the specific buffer information in the printed manual. |
Reconstitution | Please refer to the printed manual for detailed information. |
Background
Granulocyte-colony stimulating factor (G-CSF) is a growth factor and an essential cytokine belonging to the CSF family of hormone-like glycoproteins. It is produced by numerous cell types including immune and endothelial cells. Recent animal studies have also revealed that G-CSF activates multiple signaling pathways, such as Akt and also the Janus family kinase-2 and signal transducer and activation of transcription-3 (Jak2-STAT3) pathway, thereby promoting survival, proliferation, differentiation and mobilisation of haematopoietic stem and progenitor cells. G-CSF is a cytokine that have been demonstrated to improve cardiac function and perfusion in myocardial infarction. And it was initially evaluated as a stem cell mobilizer and erythropoietin as a cytoprotective agent. G-CSF prevents left ventricular remodeling after myocardial infarction by decreasing cardiomyocyte death and by increasing the number of blood vessels, suggesting the importance of direct actions of G-CSF on the myocardium rather than through mobilization and differentiation of stem cells. Accordingly, recombinant human (rh)G-CSF has been extensively used in clinical haematology and oncology to enable bone marrow transplantation or to treat chemotherapy-associated neutropenia. In preclinical study, G-CSF improved cardiac function and perfusion by angiomyogenesis and protection of cardiomyocytes in myocardial infarction.